Versuchen GOLD - Frei
Public Goods for Health is a concept which is very much a focus of WHO
BioSpectrum Asia
|March 2020
From Director General (DG), Indian Council of Medical research (ICMR) and Secretary, Department of Health Research, Dr Soumya Swaminathan went to Geneva in October 2017 to take over as the Deputy Director General (DDG) of Programmes at the World Health Organisation (WHO), to be the first Indian to hold this position. Exactly a year back, in March 2019, she took over as the WHO’s first Chief Scientist, a new position heading a division created as a part of sweeping reforms at WHO to have an explicit focus on science. A year after taking over the new and important position at an international level that is expected to create a foundation for a new department, Dr. Soumya Swaminathan spoke to Milind Kokje, chief editor, BioSpectrum while she was in Chennai, India recently about her new role, its responsibilities and other health related issues. Edited excerpts;
How would you describe your current international stint as a Chief Scientist of World Health Organisation (WHO)? How has been your experience since you took over in March 2019?
The role of the Chief Scientist is a new one and it is very interesting and a challenging position. It is a new position created in WHO. Although WHO is the science-based organization, Dr. Adhanom Tedros, Director General, WHO, wants to ensure that there is an explicit focus on science and hence this new division and a new position to head that division was created.
Our mission is two-fold. First, to ensure that WHO stays ahead of the curve to have sight on what is coming in terms of new scientific and technological developments. Not only because those developments can be leveraged for public health, but also, we need to be prepared to meet some of the new challenges, especially ethical and regulatory challenges which invariably are associated with new technology as there are risks that need to be addressed and minimized. That is one of our major focus.
Diese Geschichte stammt aus der March 2020-Ausgabe von BioSpectrum Asia.
Abonnieren Sie Magzter GOLD, um auf Tausende kuratierter Premium-Geschichten und über 9.000 Zeitschriften und Zeitungen zuzugreifen.
Sie sind bereits Abonnent? Anmelden
WEITERE GESCHICHTEN VON BioSpectrum Asia
BioSpectrum Asia
Waters launches charge detection mass spectrometry technology
US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia
The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
WHO strengthens coordination for NTD programmes and supply chain delivery
The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
All-in-one coronavirus vaccines to save millions in future pandemics
A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
NTU in Singapore introduces Master of Science course in Chinese Medicine
From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
ProSpecBio launches Activin-A recombinant protein for brain injury research
Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
PAHO publishes guide for designing AI instructions in public health
The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Prerna launches India's first MicroRNA based blood test for breast cancer screening
Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr
India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan
Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.
1 min
BioSpectrum Asia Nov 2025
Translate
Change font size
